Expert: Bispecific antibody bridging FIXa and FX, mimicking the cofactor function of activated FVIII. Enables thrombin generation in the absence of functional FVIII, providing prophylactic hemostasis.

Everyday: Mimics the missing clotting factor (Factor VIII) in hemophilia A. Like a substitute player that does the same job as the missing one, helping blood clot properly.

Targets: []

FVIIIa mimetic bispecific antibody for hemophilia A prophylaxis. Developed by Novo Nordisk using Genmab DuoBody technology. BLA submitted to FDA Sep 2025 based on FRONTIER 2/3/4 program. Competes directly with Hemlibra (emicizumab, Roche) which had $4.4B 2024 sales.